Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Dhadda, Amandeep S."'
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Iveson, Timothy J., Kerr, Rachel S., Saunders, Mark P., Cassidy, Jim, Hollander, Niels Henrik, Tabernero, Josep, Haydon, Andrew, Glimelius, Bengt, Harkin, Andrea, Allan, Karen, McQueen, John, Scudder, Claire, Boyd, Kathleen A., Briggs, Andrew, Waterston, Ashita, Medley, Louise, Wilson, Charles, Ellis, Richard, Essapen, Sharadah, Dhadda, Amandeep S., Harrison, Mark, Falk, Stephen, Raouf, Sherif, Rees, Charlotte, Olesen, Rene K., Propper, David, Bridgewater, John, Azzabi, Ashraf, Farrugia, David, Webb, Andrew, Cunningham, David, Hickish, Tamas, Weaver, Andrew, Gollins, Simon, Wasan, Harpreet S.., Paul, James, Universitat Autònoma de Barcelona
Publikováno v:
Recercat. Dipósit de la Recerca de Catalunya
instname
Recercat: Dipósit de la Recerca de Catalunya
Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)
Dipòsit Digital de Documents de la UAB
Universitat Autònoma de Barcelona
instname
Recercat: Dipósit de la Recerca de Catalunya
Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)
Dipòsit Digital de Documents de la UAB
Universitat Autònoma de Barcelona
6 months of oxaliplatin-containing chemotherapy is usually given as adjuvant treatment for stage 3 colorectal cancer. We investigated whether 3 months of oxaliplatin-containing chemotherapy would be non-inferior to the usual 6 months of treatment. Th
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=dedup_wf_001::a772a09ef13048c2095033075e2c97df
http://hdl.handle.net/2072/449826
http://hdl.handle.net/2072/449826
Autor:
Iveson, Timothy J., Kerr, Rachel S., Saunders, Mark P., Cassidy, Jim, Hollander, Niels Henrik, Tabernero, Josep, Haydon, Andrew, Glimelius, Bengy, Harkin, Andrea, Allan, Karen, McQueen, John, Scudder, Claire, Boyd, Kathleen Anne, Briggs, Andrew, Waterston, Ashita, Medley, Louise, Wilson, Charles, Ellis, Richard, Essapen, Sharadah, Dhadda, Amandeep S., Harrison, Mark, Falk, Stephen, Raouf, Sherif, Rees, Charlotte, Olesen, Rene K., Propper, David, Bridgewater, John, Azzabi, Ashraf, Farrugia, David, Webb, Andrew, Cunningham, David, Hickish, Tamas, Weaver, Andrew, Gollins, Simon, Wasan, Harpreet S., Paul, James
Publikováno v:
Iveson, T J, Kerr, R S, Saunders, M P, Cassidy, J, Hollander, N H, Tabernero, J, Haydon, A, Glimelius, B, Harkin, A, Allan, K, McQueen, J, Scudder, C, Boyd, K A, Briggs, A, Waterston, A, Medley, L, Wilson, C, Ellis, R, Essapen, S, Dhadda, A S, Harrison, M, Falk, S, Raouf, S, Rees, C, Olesen, R K, Propper, D, Bridgewater, J, Azzabi, A, Farrugia, D, Webb, A, Cunningham, D, Hickish, T, Weaver, A, Gollins, S, Wasan, H S & Paul, J 2018, ' 3 versus 6 months of adjuvant oxaliplatin-fluoropyrimidine combination therapy for colorectal cancer (SCOT) : an international, randomised, phase 3, non-inferiority trial ', Lancet Oncology, vol. 19, no. 4, pp. 562-578 . https://doi.org/10.1016/S1470-2045(18)30093-7
Background: 6 months of oxaliplatin-containing chemotherapy is usually given as adjuvant treatment for stage 3 colorectal cancer. We investigated whether 3 months of oxaliplatin-containing chemotherapy would be non-inferior to the usual 6 months of t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid_dedup__::2d57e07e4b86c46d7bdc8853680f2d02
https://doi.org/10.1016/s1470-2045(18)30093-7
https://doi.org/10.1016/s1470-2045(18)30093-7
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Boon, Ian S., Joyce, Helen, Kabir, Adnan, Goodman, Max, Brown, Victoria, Roy, Rajarshi, O'Toole, Lorcan, Dhadda, Amandeep S.
Publikováno v:
In Clinical Oncology November 2017 29(11):e204-e204
Autor:
Iveson T; Southampton University Hospital NHS Foundation Trust, Southampton, UK., Boyd KA; Institute of Health and Wellbeing, University of Glasgow, Glasgow, UK., Kerr RS; Department of Oncology, University of Oxford, Oxford, UK., Robles-Zurita J; Institute of Health and Wellbeing, University of Glasgow, Glasgow, UK., Saunders MP; The Christie Hospital NHS Foundation Trust, Manchester, UK., Briggs AH; Institute of Health and Wellbeing, University of Glasgow, Glasgow, UK., Cassidy J; Cancer Research UK Clinical Trials Unit, Institute of Cancer Sciences, University of Glasgow, Glasgow, UK., Hollander NH; Department of Oncology and Palliative Care, Zealand University Hospital, Naestved, Denmark., Tabernero J; Vall d'Hebron University Hospital and Institute of Oncology, Universitat Autònoma de Barcelona, Barcelona, Spain., Haydon A; Australasian Gastro-Intestinal Trials Group, Camperdown, NSW, Australia., Glimelius B; University of Uppsala, Uppsala, Sweden., Harkin A; Cancer Research UK Clinical Trials Unit, Institute of Cancer Sciences, University of Glasgow, Glasgow, UK., Allan K; Cancer Research UK Clinical Trials Unit, Institute of Cancer Sciences, University of Glasgow, Glasgow, UK., McQueen J; Cancer Research UK Clinical Trials Unit, Institute of Cancer Sciences, University of Glasgow, Glasgow, UK., Pearson S; Oncology Clinical Trials Office, Department of Oncology, University of Oxford, Oxford, UK., Waterston A; Beatson West of Scotland Cancer Centre, Glasgow, UK., Medley L; Royal United Hospital, Bath, UK., Wilson C; Addenbrooke's Hospital, Cambridge, UK., Ellis R; Royal Cornwall Hospitals NHS Trust, Cornwall, UK., Essapen S; St Luke's Cancer Centre, Royal Surrey County Hospital NHS Foundation Trust, Guildford, UK., Dhadda AS; Castle Hill Hospital, Hull, UK., Harrison M; Mount Vernon Cancer Centre, Northwood, UK., Falk S; Bristol Cancer Institute, Bristol, UK., Raouf S; Barking Havering and Redbridge University Hospital NHS Trust, Barking, UK., Rees C; Southampton University Hospital NHS Foundation Trust, Southampton, UK., Olesen RK; Department of Oncology, Aarhus University Hospital, Aarhus, Denmark., Propper D; Barts Cancer Institute, Queen Mary University of London, London, UK., Bridgewater J; Department of Oncology, University College London, London, UK., Azzabi A; Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, UK., Farrugia D; Gloucestershire Oncology Centre, Cheltenham General Hospital, UK., Webb A; Brighton and Sussex University Hospital Trust, Brighton, UK., Cunningham D; Royal Marsden NHS Foundation Trust, London, UK., Hickish T; Poole Hospital NHS Foundation Trust, Poole, UK., Weaver A; Department of Oncology, Oxford University Hospitals Foundation Trust, Oxford, UK., Gollins S; North Wales Cancer Treatment Centre, Rhyl, UK., Wasan H; Hammersmith Hospital, Imperial College Healthcare NHS Trust, London, UK., Paul J; The Christie Hospital NHS Foundation Trust, Manchester, UK.
Publikováno v:
Health technology assessment (Winchester, England) [Health Technol Assess] 2019 Dec; Vol. 23 (64), pp. 1-88.